Davos Alzheimer’s Collaborative and IQVIA announce a partnership to harness leading-edge data and analytics capabilities for faster Alzheimer’s research
Contact: Drew Holzapfel (dholzapfel@highlanterngroup.com)
Washington, DC – January 19, 2022 - The Davos Alzheimer’s Collaborative (DAC), a global multi-stakeholder partnership that is mobilizing the world against Alzheimer’s disease, announced today its partnership with IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to push the leading edge of Alzheimer’s research and clinical trials. The partnership will explore how IQVIA’s world-class solutions and domain expertise, together with DAC’s first-of-its-kind global research efforts, can speed and diversify new Alzheimer’s breakthroughs.
“This partnership is another important milestone for the Davos Alzheimer’s Collaborative, and we look forward to working closely with IQVIA,” said George Vradenburg, Chairman, Davos Alzheimer’s Collaborative. “New advances in treatment have accelerated investment and innovation in the space, building momentum for change and increasing the urgency for healthcare systems to be prepared for major changes in how they care for patients with the disease in the coming years.”
IQVIA is driving healthcare forward in a fast-paced, data-rich environment that will help accelerate DAC’s efforts across all three programs: Global Cohort Development, a Global Clinical Trials Support Platform, and Health System Preparedness. The organization brings capabilities that power faster, more precise clinical development; innovative platforms that enable the use, understanding, and transformation of data at scale for advanced analytical applications.
“DAC is orchestrating an ambitious global effort to combat the Alzheimer’s crisis by linking, scaling, and building on existing efforts across every sector,” said Alistair Grenfell, president, Europe, Middle East, and Africa, IQVIA. “We are excited to partner with them on this ambitious endeavor.”
DAC is completing the foundational phase fund-raise with over $25 million in commitments to advance its projects, in addition to invaluable contributions of time and talent, from supporters including Eli Lilly & Company, Roche, Biogen, Eisai, Otsuka, C2N, Cognivue, Linus Health, and Cogstate. DAC intends to announce further progress toward these goals during the World Economic Forum annual meeting in January 2022.
To learn more visit https://www.davosalzheimerscollaborative.org.
About the Davos Alzheimer’s Collaborative
Launched at the World Economic Forum’s 2021 meeting on The Davos Agenda, The Davos Alzheimer’s Collaborative is a multi-stakeholder partnership committed to aligning stakeholders with a new vision for our collective global response against the challenges Alzheimer’s presents to patients, caregivers and healthcare infrastructures. Convened by The World Economic Forum and The Global CEO Initiative on Alzheimer’s Disease (CEOi) and fueled by a mission of service to the estimated 150 million families and half a billion people inevitably impacted by this disease by 2050, DAC is a collaborative for the benefit of all people, in all places.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 77,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
